amiodarone has been researched along with Chronic Illness in 127 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation." | 9.15 | Dronedarone in high-risk permanent atrial fibrillation. ( Afzal, R; Alings, M; Amerena, J; Atar, D; Avezum, Á; Baret-Cormel, L; Blomström, P; Borggrefe, M; Budaj, A; Camm, AJ; Chen, SA; Ching, CK; Chrolavicius, S; Commerford, P; Connolly, SJ; Dans, A; Davy, JM; Delacrétaz, E; Di Pasquale, G; Diaz, R; Dorian, P; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Granger, CB; Halperin, JL; Heidbüchel, H; Hohnloser, SH; Joyner, C; Kautzner, J; Kim, JS; Lanas, F; Lewis, BS; Merino, JL; Morillo, C; Murin, J; Narasimhan, C; Paolasso, E; Parkhomenko, A; Peters, NS; Sim, KH; Staiger, C; Stiles, MK; Tanomsup, S; Toivonen, L; Tomcsányi, J; Torp-Pedersen, C; Tse, HF; Vardas, P; Vinereanu, D; Weinling, E; Xavier, D; Yusuf, S; Zhu, J; Zhu, JR, 2011) |
| "To explore the therapeutic effects of amiodarone and metoprolol, either alone or in combination, on chronic heart failure (CHF) complicated by ventricular arrhythmia." | 9.14 | [Therapeutic effects of amiodarone and metoprolol on chronic heart failure complicated by ventricular arrhythmia]. ( He, BB; Huang, GH; Lü, HS, 2009) |
| "To assess the effects of amiodarone and diltiazem on atrial fibrillation (AF) induced atrial electrical remodeling and their clinical implications." | 9.10 | Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study. ( Dermitzaki, DN; Kallergis, EM; Kambouraki, DC; Kanoupakis, EM; Manios, EG; Mavrakis, HE; Vardas, PE, 2003) |
| "Amiodarone and propafenone appear to be safe and equally effective in the termination of chronic atrial fibrillation." | 9.09 | Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. ( Chlouverakis, GI; Igoumenidis, NE; Kochiadakis, GE; Parthenakis, FI; Vardas, PE, 1999) |
| "We sought to assess the efficacy and safety of amiodarone for restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation in a prospective, randomized, double blind trial." | 9.09 | Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial. ( Chiale, PA; Elizari, MV; Galperín, J; Ledesma, R; Molina, RT; Scapín, AO; Vázquez Blanco, M, 2001) |
| "Ninety-two patients with persistent atrial fibrillation (>2 weeks duration) were prospectively randomized into three matched groups: A (n=31, oral amiodarone 400 mg." | 9.09 | Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. ( Aschieri, D; Capucci, A; Piepoli, MF; Rosi, A; Villani, GQ, 2000) |
| "Low-dose amiodarone is effective for maintaining sinus rhythm in patients with difficult to treat chronic atrial fibrillation or flutter and is associated with a low incidence of serious side effects." | 9.07 | Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. ( Crijns, HJ; Gosselink, AT; Hillige, H; Lie, KI; Van Gelder, IC; Wiesfeld, AC, 1992) |
| "Cardioversion followed by low-dose amiodarone to maintain normal sinus rhythm appears to be a relatively safe and effective treatment for patients with chronic atrial fibrillation." | 8.79 | Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. ( Birkmeyer, JD; Disch, DL; Greenberg, ML; Holzberger, PT; Malenka, DJ, 1994) |
| "Hypothyroidism, especially the subclinical form, frequently occurs in patients affected by CHF receiving amiodarone therapy." | 7.78 | Incidence and prevalence of hypothyroidism in patients affected by chronic heart failure: role of amiodarone. ( Catanzaro, R; Ciccone, MM; Favale, S; Forleo, C; Giagulli, VA; Guastamacchia, E; Guida, P; Iacoviello, M; Licchelli, B; Monzani, F; Puzzovivo, A; Tafaro, E; Triggiani, V, 2012) |
| "Intermittent intravenous inotropic agents combined with prophylactic oral amiodarone seem to improve the outcomes of patients with end-stage chronic heart failure." | 7.75 | Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure. ( Bonios, M; Drakos, SG; Kaldara, E; Kanakakis, JV; Katsaros, F; Nanas, JN; Nanas, S; Pantsios, C, 2009) |
| "Amiodarone/Silymarin Treatment for Sustained Atrial Flutter." | 7.72 | Combined amiodarone and silymarin treatment, but not amiodarone alone, prevents sustained atrial flutter in dogs. ( Besch, H; Vereckei, A; Zipes, DP, 2003) |
| "The aim of our study was to assess (1) the effectiveness of repeat DC cardioversion in patients with chronic atrial fibrillation after pretreatment with amiodarone, and (2) the efficacy of amiodarone in maintaining sinus rhythm after repeat cardioversion." | 7.69 | Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion. ( Górecki, A; Kraska, T; Opolski, G; Stanisławska, J; Swiecicka, G; Torbicki, A, 1997) |
| "The purpose of this study was to examine the efficacy and safety of amiodarone to maintain sinus rhythm in patients with refractory atrial fibrillation or flutter." | 7.69 | Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. ( Chun, SH; Middlekauff, HR; Nademanee, K; Sager, PT; Singh, BN; Stevenson, WG, 1995) |
| "The effectiveness and safety of quinidine in the conversion of chronic atrial fibrillation after administration of amiodarone was assessed in 15 patients." | 7.68 | The effectiveness and safety of the simultaneous administration of quinidine and amiodarone in the conversion of chronic atrial fibrillation. ( Ansari-Leesar, M; Cohen, A; Faitel, K; Frumin, H; Kerin, NZ; Narala, C, 1993) |
| "Thirty consecutive patients with chronic rheumatic atrial fibrillation (AF) > or = 3 months after successful mitral valve surgery and left atrial diameter < or = 60 mm were treated with oral amiodarone." | 7.68 | Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery. ( Essop, MR; Röthlisberger, C; Sareli, P; Skoularigis, J; Skudicky, D; Wisenbaugh, T, 1993) |
| "To evaluate the efficacy and safety of long-term empiric amiodarone therapy in patients with recurrent Sustained Ventricular Tachycardia (SVT) and Chronic Chagasic Myocarditis (CCM)." | 7.68 | [Empiric therapy with amiodarone in patients with chronic Chagas cardiomyopathy and sustained ventricular tachycardia]. ( Bellotti, G; Lee, JH; Pileggi, F; Scanavacca, MI; Sosa, EA, 1990) |
| "We report four cases of life-threatening amiodarone iodine-induced thyrotoxicosis." | 7.68 | Life-threatening thyrotoxicosis induced by amiodarone in patients with benign heart disease. ( Georges, JL; Lenormand, ME; Normand, JP; Schwob, J, 1992) |
| "Fourteen patients with established atrial fibrillation (longer than three months) that was refractory to treatment were studied to compare the clinical and electrophysiological effects of amiodarone and bepridil." | 7.67 | A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation. ( Krikler, DM; McKenna, WJ; Perelman, MS; Rowland, E, 1987) |
| "Oral amiodarone was administered to 24 patients with chronic chagasic myocarditis (CCM) and malignant ventricular arrhythmias." | 7.67 | Efficacy of amiodarone during long-term treatment of malignant ventricular arrhythmias in patients with chronic chagasic myocarditis. ( Chiale, PA; Elizari, MV; Halpern, MS; Lázzari, JO; Nau, GJ; Przybylski, J; Rosenbaum, MB; Tambussi, AM, 1984) |
| "A very low dose of amiodarone results in adequate long-term efficacy and is safe for maintaining sinus rhythm in patients with CAF and RHD post intervention after successful DC cardioversion." | 6.72 | Long-term efficacy and safety of very-low-dose amiodarone treatment for the maintenance of sinus rhythm in patients with chronic atrial fibrillation after successful direct-current cardioversion. ( Chang, MH; Chang, TC; Chen, CY; Chou, P; Fu, CY; Jong, GP; Ma, TC; Tien, LY, 2006) |
| "Amiodarone and quinidine were equally effective at 24 hours in converting CAF (eight [47%] of 17 patients in the quinidine group vs 12 [44%] of 27 patients in the amiodarone group; P, not significant)." | 6.68 | The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. ( Faitel, K; Kerin, NZ; Naini, M, 1996) |
| "Amiodarone hydrochloride was given orally to the animals every day in a dose of 200 mg/day for the first 7 days followed by 100 mg/day for the following 21 days." | 5.43 | Impacts of Surgically Performed Renal Denervation on the Cardiovascular and Electrophysiological Variables in the Chronic Atrioventricular Block Dogs - Comparison With Those of Amiodarone Treatment. ( Ando, K; Aonuma, K; Cao, X; Izumi-Nakaseko, H; Murakoshi, N; Nakamura, Y; Nakazato, Y; Ohara, H; Sato, A; Sugiyama, A; Takahara, A; Wada, T; Yokoyama, H, 2016) |
| "The time to optimal ventricular arrhythmia control was shorter for group B (20 +/- 18 vs 105 +/- 83 days, p less than 0." | 5.27 | Intravenous and oral loading versus oral loading alone with amiodarone for chronic refractory ventricular arrhythmias. ( Blevins, RD; Faitel, K; Frumin, H; Kerin, NZ; Rubenfire, M, 1985) |
| "Amiodarone therapy, especially chronic, can result in difficult ventricular fibrillation (VF) inductions during implantable cardioverter defibrillator (ICD) testing." | 5.17 | Effectiveness of VF induction with DC fibber versus conventional induction methods in patients on chronic amiodarone therapy. ( Gupta, MS; Kim, MH; Rubenstein, JC, 2013) |
| "In patients with persistent atrial fibrillation on amiodarone and a renin-angiotensin-aldosterone system inhibitor, the addition of n-3 PUFAs 2 g/d improves the probability of the maintenance of sinus rhythm after direct current cardioversion." | 5.15 | n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. ( Campia, U; Cesana, BM; Dei Cas, L; Gheorghiade, M; Manerba, A; Milesi, G; Nodari, S; Triggiani, M, 2011) |
| "Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation." | 5.15 | Dronedarone in high-risk permanent atrial fibrillation. ( Afzal, R; Alings, M; Amerena, J; Atar, D; Avezum, Á; Baret-Cormel, L; Blomström, P; Borggrefe, M; Budaj, A; Camm, AJ; Chen, SA; Ching, CK; Chrolavicius, S; Commerford, P; Connolly, SJ; Dans, A; Davy, JM; Delacrétaz, E; Di Pasquale, G; Diaz, R; Dorian, P; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Granger, CB; Halperin, JL; Heidbüchel, H; Hohnloser, SH; Joyner, C; Kautzner, J; Kim, JS; Lanas, F; Lewis, BS; Merino, JL; Morillo, C; Murin, J; Narasimhan, C; Paolasso, E; Parkhomenko, A; Peters, NS; Sim, KH; Staiger, C; Stiles, MK; Tanomsup, S; Toivonen, L; Tomcsányi, J; Torp-Pedersen, C; Tse, HF; Vardas, P; Vinereanu, D; Weinling, E; Xavier, D; Yusuf, S; Zhu, J; Zhu, JR, 2011) |
| "To explore the therapeutic effects of amiodarone and metoprolol, either alone or in combination, on chronic heart failure (CHF) complicated by ventricular arrhythmia." | 5.14 | [Therapeutic effects of amiodarone and metoprolol on chronic heart failure complicated by ventricular arrhythmia]. ( He, BB; Huang, GH; Lü, HS, 2009) |
| "A total of 146 patients with a mean (+/-SD) age of 57+/-9 years who had chronic atrial fibrillation were randomly assigned to receive amiodarone and undergo two cardioversions during the first three months alone (the control group) or in combination with circumferential pulmonary-vein ablation." | 5.12 | Circumferential pulmonary-vein ablation for chronic atrial fibrillation. ( Agricola, E; Augello, G; Bates, ER; Bogun, F; Chugh, A; Good, E; Lehmann, MH; Morady, F; Oral, H; Pappone, C; Pelosi, F; Sala, S; Santinelli, V; Vicedomini, G, 2006) |
| "We prospectively studied 144 patients with chronic rheumatic atrial fibrillation in a double-blind protocol in which rhythm control (group I), comprising 48 patients each with amiodarone (group Ia) and placebo (group Ib), were compared with each other and with patients in a ventricular rate control group (group II) in which the effects by diltiazem were determined (n = 48, open-label)." | 5.11 | Control of heart rate versus rhythm in rheumatic atrial fibrillation: a randomized study. ( Goyal, V; Gupta, A; Karnad, D; Kulkarni, H; Lokhandwala, Y; Naik, A; Singh, BN; Vora, A, 2004) |
| "Patients treated with amiodarone plus irbesartan had a lower rate of recurrence of atrial fibrillation than did patients treated with amiodarone alone." | 5.10 | Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. ( Bernal, E; Bueno, MG; Cabeza, P; Cano, JM; Cano, L; Madrid, AH; Marín, I; Moro, C; Peña, G; Rebollo, JM; Rodriguez, A, 2002) |
| "To assess the effects of amiodarone and diltiazem on atrial fibrillation (AF) induced atrial electrical remodeling and their clinical implications." | 5.10 | Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study. ( Dermitzaki, DN; Kallergis, EM; Kambouraki, DC; Kanoupakis, EM; Manios, EG; Mavrakis, HE; Vardas, PE, 2003) |
| "We sought to assess the efficacy and safety of amiodarone for restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation in a prospective, randomized, double blind trial." | 5.09 | Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial. ( Chiale, PA; Elizari, MV; Galperín, J; Ledesma, R; Molina, RT; Scapín, AO; Vázquez Blanco, M, 2001) |
| "Ninety-two patients with persistent atrial fibrillation (>2 weeks duration) were prospectively randomized into three matched groups: A (n=31, oral amiodarone 400 mg." | 5.09 | Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. ( Aschieri, D; Capucci, A; Piepoli, MF; Rosi, A; Villani, GQ, 2000) |
| "Amiodarone and propafenone appear to be safe and equally effective in the termination of chronic atrial fibrillation." | 5.09 | Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. ( Chlouverakis, GI; Igoumenidis, NE; Kochiadakis, GE; Parthenakis, FI; Vardas, PE, 1999) |
| "Low-dose amiodarone is effective for maintaining sinus rhythm in patients with difficult to treat chronic atrial fibrillation or flutter and is associated with a low incidence of serious side effects." | 5.07 | Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. ( Crijns, HJ; Gosselink, AT; Hillige, H; Lie, KI; Van Gelder, IC; Wiesfeld, AC, 1992) |
| " For patients who have a history of sustained ventricular tachycardia(VT) or ventricular fibrillation(VF) amiodarone or an implantable cardioverter defibrillator(ICD) should be considered, and these therapy may benefit some high risk patients who have nonsustained VT." | 4.81 | [Heart failure]. ( Komuro, I; Yonezawa, M, 2002) |
| "In the absence of randomized, controlled trials of low-dose amiodarone in atrial fibrillation or a randomized, controlled trial of ventricular rate control versus antifibrillatory therapy, a Markov decision analysis is useful in comparing different therapeutic strategies for atrial fibrillation." | 4.79 | Therapeutic strategies for atrial fibrillation. The value of decision analysis. ( Disch, DL; Greenberg, ML; Malenka, DJ, 1996) |
| "Cardioversion followed by low-dose amiodarone to maintain normal sinus rhythm appears to be a relatively safe and effective treatment for patients with chronic atrial fibrillation." | 4.79 | Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. ( Birkmeyer, JD; Disch, DL; Greenberg, ML; Holzberger, PT; Malenka, DJ, 1994) |
| "Patients with chronic Chagas cardiopathy (CCC), which may be associated with cardiac arrhythmias, frequently use amiodarone, an antiarrhythmic drug that, experimentally, appears to modulate the cardiac autonomic function." | 3.88 | Cardiac autonomic modulation and long-term use of amiodarone in patients with chronic Chagasic cardiopathy. ( Correia, D; de Almeida, RS; Dias da Silva, VJ; Fortes Silva, HE; Llaguno, M; Resende, LAPR; Silveira, DB, 2018) |
| "Hypothyroidism, especially the subclinical form, frequently occurs in patients affected by CHF receiving amiodarone therapy." | 3.78 | Incidence and prevalence of hypothyroidism in patients affected by chronic heart failure: role of amiodarone. ( Catanzaro, R; Ciccone, MM; Favale, S; Forleo, C; Giagulli, VA; Guastamacchia, E; Guida, P; Iacoviello, M; Licchelli, B; Monzani, F; Puzzovivo, A; Tafaro, E; Triggiani, V, 2012) |
| "Intermittent intravenous inotropic agents combined with prophylactic oral amiodarone seem to improve the outcomes of patients with end-stage chronic heart failure." | 3.75 | Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure. ( Bonios, M; Drakos, SG; Kaldara, E; Kanakakis, JV; Katsaros, F; Nanas, JN; Nanas, S; Pantsios, C, 2009) |
| "We evaluated the hypothesis that a relationship exists between inflammation and the outcome of pharmaceutical cardioversion with amiodarone in recent onset atrial fibrillation." | 3.74 | Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome. ( Dragomanovits, S; Kalogeropoulos, AS; Kremastinos, DT; Papathanasiou, S; Rigopoulos, AG; Rizos, I; Sakadakis, EA; Tsiodras, S, 2007) |
| "The aim of the article was to assess the efficacy of treatment of atrial fibrillation (AE) and congestive heart failure (CHF) with Enalapril in combination with Cordaron." | 3.74 | [Dynamics of echocardiographic changes and the tactic of optimal therapy in patients with atrial fibrillation with chronical heart failure]. ( Abuladze, GV; Dzhashi, IA; Dzhindzholiia, NA; Gudzhedzhiani, LA; Narsiia, EV, 2007) |
| "An 80-year-old man, who had been taking the antiarrhythmic drug amiodarone for chronic atrial fibrillation since October 2004, developed dyspnea and fever in June 2005, and was admitted to our hospital." | 3.73 | [A case of drug-induced pneumonitis due to amiodarone]. ( Hayashi, N; Hirose, M; Horiguchi, T; Itou, T; Kobayashi, K; Kondo, R; Ouhira, D; Shiga, M; Torigoe, H, 2006) |
| "Amiodarone/Silymarin Treatment for Sustained Atrial Flutter." | 3.72 | Combined amiodarone and silymarin treatment, but not amiodarone alone, prevents sustained atrial flutter in dogs. ( Besch, H; Vereckei, A; Zipes, DP, 2003) |
| " The incidence of clinical torsade de pointes (TdP) associated with amiodarone has been reported to be low and the present study compared the proarrhythmic potential of amiodarone with that of a selective IKr channel blocker, sematilide, using a canine chronic atrioventrucular block model." | 3.71 | Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model. ( Hashimoto, K; Ishida, Y; Kugiyama, K; Satoh, Y; Sugiyama, A; Yoneyama, M; Yoshida, H, 2002) |
| "The aim of our study was to assess (1) the effectiveness of repeat DC cardioversion in patients with chronic atrial fibrillation after pretreatment with amiodarone, and (2) the efficacy of amiodarone in maintaining sinus rhythm after repeat cardioversion." | 3.69 | Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion. ( Górecki, A; Kraska, T; Opolski, G; Stanisławska, J; Swiecicka, G; Torbicki, A, 1997) |
| "The purpose of this study was to examine the efficacy and safety of amiodarone to maintain sinus rhythm in patients with refractory atrial fibrillation or flutter." | 3.69 | Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. ( Chun, SH; Middlekauff, HR; Nademanee, K; Sager, PT; Singh, BN; Stevenson, WG, 1995) |
| "Thirty consecutive patients with chronic rheumatic atrial fibrillation (AF) > or = 3 months after successful mitral valve surgery and left atrial diameter < or = 60 mm were treated with oral amiodarone." | 3.68 | Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery. ( Essop, MR; Röthlisberger, C; Sareli, P; Skoularigis, J; Skudicky, D; Wisenbaugh, T, 1993) |
| "We report four cases of life-threatening amiodarone iodine-induced thyrotoxicosis." | 3.68 | Life-threatening thyrotoxicosis induced by amiodarone in patients with benign heart disease. ( Georges, JL; Lenormand, ME; Normand, JP; Schwob, J, 1992) |
| "To evaluate the efficacy and safety of long-term empiric amiodarone therapy in patients with recurrent Sustained Ventricular Tachycardia (SVT) and Chronic Chagasic Myocarditis (CCM)." | 3.68 | [Empiric therapy with amiodarone in patients with chronic Chagas cardiomyopathy and sustained ventricular tachycardia]. ( Bellotti, G; Lee, JH; Pileggi, F; Scanavacca, MI; Sosa, EA, 1990) |
| "The effectiveness and safety of quinidine in the conversion of chronic atrial fibrillation after administration of amiodarone was assessed in 15 patients." | 3.68 | The effectiveness and safety of the simultaneous administration of quinidine and amiodarone in the conversion of chronic atrial fibrillation. ( Ansari-Leesar, M; Cohen, A; Faitel, K; Frumin, H; Kerin, NZ; Narala, C, 1993) |
| "Oral amiodarone was administered to 24 patients with chronic chagasic myocarditis (CCM) and malignant ventricular arrhythmias." | 3.67 | Efficacy of amiodarone during long-term treatment of malignant ventricular arrhythmias in patients with chronic chagasic myocarditis. ( Chiale, PA; Elizari, MV; Halpern, MS; Lázzari, JO; Nau, GJ; Przybylski, J; Rosenbaum, MB; Tambussi, AM, 1984) |
| "Fourteen patients with established atrial fibrillation (longer than three months) that was refractory to treatment were studied to compare the clinical and electrophysiological effects of amiodarone and bepridil." | 3.67 | A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation. ( Krikler, DM; McKenna, WJ; Perelman, MS; Rowland, E, 1987) |
| "This study suggests that Tc-99m sestamibi may be an alternative tracer for thyroid scintigraphy and uptake measurement of patients on chronic use of amiodarone." | 2.75 | Tc-99m sestamibi thyroid imaging in patients on chronic amiodarone treatment: a comparison with Tc-99m pertechnetate imaging. ( Amorim, BJ; Camargo, EE; de Almeida, EA; de Oliveira Santos, A; Etchebehere, EC; Guariento, MH; Lima, MC; Oki, GC; Ramos, CD; Tambascia, MA; Zantut-Wittmann, DE, 2010) |
| "And amiodarone was given from the third day before the surgery and lasted for 3 months thereafter." | 2.72 | [The clinical study of circumferential ablation around orifice of pulmonary vein by radiofrequency energy with chronic atrial fibrillation undergoing rheumatic valvular heart surgery]. ( Bai, BJ; Du, RY; Wang, CG; Wang, JZ; Xin, LP; Zhong, ZH, 2006) |
| "A very low dose of amiodarone results in adequate long-term efficacy and is safe for maintaining sinus rhythm in patients with CAF and RHD post intervention after successful DC cardioversion." | 2.72 | Long-term efficacy and safety of very-low-dose amiodarone treatment for the maintenance of sinus rhythm in patients with chronic atrial fibrillation after successful direct-current cardioversion. ( Chang, MH; Chang, TC; Chen, CY; Chou, P; Fu, CY; Jong, GP; Ma, TC; Tien, LY, 2006) |
| "Amiodarone has been the only drug so far reported to give a combination of high efficacy and low frequency of serious side effects such as ventricular tachycardia and shock." | 2.69 | Amiodarone for rapid cardioversion of chronic atrial tachyarrhythmia? ( Møller, S; Nielsen, KD, 2000) |
| "Amiodarone and quinidine were equally effective at 24 hours in converting CAF (eight [47%] of 17 patients in the quinidine group vs 12 [44%] of 27 patients in the amiodarone group; P, not significant)." | 2.68 | The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. ( Faitel, K; Kerin, NZ; Naini, M, 1996) |
| "Amiodarone was well tolerated and propafenone produced minor digestive and neurosensory troubles in about half the cases, only in one patient a more pronounced arrhythmogenic effect was observed." | 2.66 | [Comparative study of the efficacy of propafenone and amiodarone in the treatment of chronic ventricular extrasystole]. ( Cosnay, P; Fauchier, JP; Huguet, R; Moquet, B; Rouesnel, P; Wajman, A, 1986) |
| "Hyperthyroidism, is less frequent in this clinical context but it necessitates of immediate treatment because of its negative effects on cardiovascular balance." | 2.58 | Dysthyroidism and Chronic Heart Failure: Pathophysiological Mechanisms and Therapeutic Approaches. ( Gioia, MI; Iacoviello, M; Parisi, G; Rizzo, C; Triggiani, V, 2018) |
| "Amiodarone was introduced as an antiarrhythmic compound in the early 1970s and was approved in the U." | 2.40 | Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. ( Singh, BN, 1997) |
| "Amiodarone hydrochloride was given orally to the animals every day in a dose of 200 mg/day for the first 7 days followed by 100 mg/day for the following 21 days." | 1.43 | Impacts of Surgically Performed Renal Denervation on the Cardiovascular and Electrophysiological Variables in the Chronic Atrioventricular Block Dogs - Comparison With Those of Amiodarone Treatment. ( Ando, K; Aonuma, K; Cao, X; Izumi-Nakaseko, H; Murakoshi, N; Nakamura, Y; Nakazato, Y; Ohara, H; Sato, A; Sugiyama, A; Takahara, A; Wada, T; Yokoyama, H, 2016) |
| "The average time to recurrence of AF after RFCA was 9." | 1.38 | Prediction of long-term outcomes of catheter ablation of persistent atrial fibrillation by parameters of preablation DC cardioversion. ( Ban, JE; Choi, JI; Kang, JH; Kim, MN; Kim, S; Kim, YH; Lee, DI; Lim, HE; Park, SW; Park, YM, 2012) |
| "During a 4-week follow-up, AF recurrence was observed in 41 patients (65." | 1.37 | Noninvasive time and frequency predictors of long-standing atrial fibrillation early recurrence after electrical cardioversion. ( Alcaraz, R; Hornero, F; Rieta, JJ, 2011) |
| "Amiodarone was administered orally in a dose of 200 mg/body per day for the initial 7 days followed by 100 mg for the following 21 days (n = 7)." | 1.34 | In vivo electropharmacological effects of amiodarone and candesartan on atria of chronic atrioventricular block dogs. ( Aonuma, K; Matsumoto, M; Nakamura, Y; Sugiyama, A; Takahara, A; Wang, K, 2007) |
| "Amiodarone pulmonary toxicity is a serious adverse effect that can be fatal." | 1.31 | Diagnosis of amiodarone pulmonary toxicity with high-resolution computerized tomographic scan. ( Narula, D; Siniakowicz, RM; Steinberg, JS; Suster, B, 2001) |
| "The early recurrences of AF were initiated with consecutive APDs; but the numbers of APD in the first 30 seconds after cardioversion were similar between group 1 and 2." | 1.30 | Early recurrence of atrial fibrillation after external cardioversion. ( Chang, MS; Chen, CC; Chen, SA; Ding, YA; Hsieh, MH; Hsu, TL; Lin, YK; Tai, CT; Tsai, CF; Yu, WC, 1999) |
| "Celiprolol is a cardioselective beta-blocker with a partial beta-2 agonist activity and an alpha-2 blocking activity, with a minimal depressant effect on heart rate." | 1.29 | [Combination of celiprolol and amiodarone in the treatment of recurrent ventricular tachycardia]. ( Coutte, R; Frank, R; Hidden, F; Himbert, C; Naditch, L; Tonet, J, 1996) |
| "Arrhythmias are frequent and associated with a poor prognosis, especially when they arise from the ventricle." | 1.28 | [Treatment of arrhythmias in chronic cardiac insufficiency]. ( Drieu, L; Motté, G; Slama, M, 1990) |
| " Daily dosage was 200 mg in 2 cases, 400 mg then 200 mg in the third one, and duration of therapy ranged between 36 and 60 months." | 1.27 | Chronic liver disease after low daily doses of amiodarone. Report of three cases. ( Babany, G; Carcone, B; Dhumeaux, D; Mallat, A; Saint-Marc Girardin, MF; Zafrani, ES, 1986) |
| "The time to optimal ventricular arrhythmia control was shorter for group B (20 +/- 18 vs 105 +/- 83 days, p less than 0." | 1.27 | Intravenous and oral loading versus oral loading alone with amiodarone for chronic refractory ventricular arrhythmias. ( Blevins, RD; Faitel, K; Frumin, H; Kerin, NZ; Rubenfire, M, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (18.11) | 18.7374 |
| 1990's | 41 (32.28) | 18.2507 |
| 2000's | 45 (35.43) | 29.6817 |
| 2010's | 17 (13.39) | 24.3611 |
| 2020's | 1 (0.79) | 2.80 |
| Authors | Studies |
|---|---|
| Sileno, S | 1 |
| Chirila, RM | 1 |
| Harris, DM | 1 |
| Rambarat, CA | 1 |
| Winchester, DE | 1 |
| Rizzo, C | 1 |
| Gioia, MI | 1 |
| Parisi, G | 1 |
| Triggiani, V | 2 |
| Iacoviello, M | 2 |
| Fortes Silva, HE | 1 |
| de Almeida, RS | 1 |
| Silveira, DB | 1 |
| Llaguno, M | 1 |
| Resende, LAPR | 1 |
| Dias da Silva, VJ | 2 |
| Correia, D | 1 |
| Rubenstein, JC | 1 |
| Gupta, MS | 1 |
| Kim, MH | 1 |
| Caldentey, G | 1 |
| Khairy, P | 1 |
| Roy, D | 1 |
| Leduc, H | 1 |
| Talajic, M | 1 |
| Racine, N | 1 |
| White, M | 1 |
| O'Meara, E | 1 |
| Guertin, MC | 1 |
| Rouleau, JL | 1 |
| Ducharme, A | 1 |
| Otero, MJ | 1 |
| Moreno-Gómez, AM | 1 |
| Santos-Ramos, B | 1 |
| Agra, Y | 1 |
| Rizzo, LF | 1 |
| Mana, DL | 1 |
| Bruno, OD | 1 |
| Besli, F | 1 |
| Basar, C | 1 |
| Kecebas, M | 1 |
| Turker, Y | 1 |
| Wada, T | 1 |
| Ohara, H | 1 |
| Nakamura, Y | 2 |
| Yokoyama, H | 1 |
| Cao, X | 1 |
| Izumi-Nakaseko, H | 1 |
| Ando, K | 1 |
| Murakoshi, N | 1 |
| Sato, A | 1 |
| Aonuma, K | 2 |
| Takahara, A | 2 |
| Nakazato, Y | 1 |
| Sugiyama, A | 3 |
| Cadiou, G | 1 |
| Varin, R | 1 |
| Levesque, H | 1 |
| Grassi, V | 1 |
| Benichou, J | 1 |
| Tiret, I | 1 |
| Dieu, B | 1 |
| Lecam-Duchez, V | 1 |
| Borg, JY | 1 |
| Muller, JM | 1 |
| Benhamou, Y | 1 |
| Marie, I | 1 |
| Meinertz, T | 3 |
| Willems, S | 1 |
| Drakos, SG | 1 |
| Kanakakis, JV | 1 |
| Nanas, S | 1 |
| Bonios, M | 1 |
| Kaldara, E | 1 |
| Katsaros, F | 1 |
| Pantsios, C | 1 |
| Nanas, JN | 1 |
| Bestetti, R | 1 |
| Cardinalli-Neto, A | 1 |
| Paniz-Mondolfi, AE | 1 |
| Pérez-Alvarez, AM | 1 |
| Lanza, G | 1 |
| Márquez, E | 1 |
| Concepción, JL | 1 |
| Lü, HS | 1 |
| He, BB | 1 |
| Huang, GH | 1 |
| Oki, GC | 1 |
| Zantut-Wittmann, DE | 1 |
| de Oliveira Santos, A | 1 |
| Guariento, MH | 1 |
| Tambascia, MA | 1 |
| de Almeida, EA | 1 |
| Amorim, BJ | 1 |
| Lima, MC | 1 |
| Etchebehere, EC | 1 |
| Camargo, EE | 1 |
| Ramos, CD | 1 |
| Pires, LM | 1 |
| Leiria, TL | 1 |
| de Lima, GG | 1 |
| Kruse, ML | 1 |
| Nesralla, IA | 1 |
| Kalil, RA | 1 |
| Onan, B | 1 |
| Onan, IS | 1 |
| Caynak, B | 1 |
| Korkmaz, AA | 1 |
| Sağbaş, E | 1 |
| Sanisoğlu, I | 1 |
| Oklü, E | 1 |
| Akpınar, B | 1 |
| Alcaraz, R | 1 |
| Hornero, F | 1 |
| Rieta, JJ | 1 |
| Nodari, S | 1 |
| Triggiani, M | 1 |
| Campia, U | 1 |
| Manerba, A | 1 |
| Milesi, G | 1 |
| Cesana, BM | 1 |
| Gheorghiade, M | 1 |
| Dei Cas, L | 1 |
| Connolly, SJ | 1 |
| Camm, AJ | 1 |
| Halperin, JL | 1 |
| Joyner, C | 1 |
| Alings, M | 1 |
| Amerena, J | 1 |
| Atar, D | 1 |
| Avezum, Á | 1 |
| Blomström, P | 1 |
| Borggrefe, M | 1 |
| Budaj, A | 1 |
| Chen, SA | 2 |
| Ching, CK | 1 |
| Commerford, P | 1 |
| Dans, A | 1 |
| Davy, JM | 1 |
| Delacrétaz, E | 1 |
| Di Pasquale, G | 1 |
| Diaz, R | 1 |
| Dorian, P | 1 |
| Flaker, G | 1 |
| Golitsyn, S | 1 |
| Gonzalez-Hermosillo, A | 1 |
| Granger, CB | 1 |
| Heidbüchel, H | 1 |
| Kautzner, J | 1 |
| Kim, JS | 1 |
| Lanas, F | 1 |
| Lewis, BS | 1 |
| Merino, JL | 1 |
| Morillo, C | 1 |
| Murin, J | 1 |
| Narasimhan, C | 1 |
| Paolasso, E | 1 |
| Parkhomenko, A | 1 |
| Peters, NS | 1 |
| Sim, KH | 1 |
| Stiles, MK | 1 |
| Tanomsup, S | 1 |
| Toivonen, L | 1 |
| Tomcsányi, J | 1 |
| Torp-Pedersen, C | 1 |
| Tse, HF | 2 |
| Vardas, P | 1 |
| Vinereanu, D | 1 |
| Xavier, D | 1 |
| Zhu, J | 1 |
| Zhu, JR | 1 |
| Baret-Cormel, L | 1 |
| Weinling, E | 1 |
| Staiger, C | 1 |
| Yusuf, S | 1 |
| Chrolavicius, S | 1 |
| Afzal, R | 1 |
| Hohnloser, SH | 2 |
| Monzani, F | 1 |
| Puzzovivo, A | 1 |
| Guida, P | 1 |
| Forleo, C | 1 |
| Ciccone, MM | 1 |
| Catanzaro, R | 1 |
| Tafaro, E | 1 |
| Licchelli, B | 1 |
| Giagulli, VA | 1 |
| Guastamacchia, E | 1 |
| Favale, S | 1 |
| Kang, JH | 1 |
| Lee, DI | 1 |
| Kim, S | 1 |
| Kim, MN | 1 |
| Park, YM | 1 |
| Ban, JE | 1 |
| Choi, JI | 1 |
| Lim, HE | 1 |
| Park, SW | 1 |
| Kim, YH | 1 |
| Madrid, AH | 1 |
| Bueno, MG | 1 |
| Rebollo, JM | 1 |
| Marín, I | 1 |
| Peña, G | 1 |
| Bernal, E | 1 |
| Rodriguez, A | 1 |
| Cano, L | 1 |
| Cano, JM | 1 |
| Cabeza, P | 1 |
| Moro, C | 1 |
| Yonezawa, M | 1 |
| Komuro, I | 1 |
| Yoshida, H | 1 |
| Satoh, Y | 1 |
| Ishida, Y | 1 |
| Yoneyama, M | 1 |
| Kugiyama, K | 1 |
| Hashimoto, K | 1 |
| Kirkali, Z | 1 |
| Kanorskiĭ, SG | 2 |
| Zingilevskiĭ, KB | 1 |
| Kohno, M | 1 |
| Ohkusa, T | 1 |
| Matsuzaki, M | 1 |
| Manios, EG | 1 |
| Mavrakis, HE | 1 |
| Kanoupakis, EM | 1 |
| Kallergis, EM | 1 |
| Dermitzaki, DN | 1 |
| Kambouraki, DC | 1 |
| Vardas, PE | 2 |
| Vereckei, A | 1 |
| Zipes, DP | 1 |
| Besch, H | 1 |
| Scherer, M | 1 |
| Dzemali, O | 1 |
| Aybek, T | 1 |
| Wimmer-Greinecker, G | 1 |
| Moritz, A | 1 |
| Mazur, NA | 1 |
| Sosonkina, OV | 1 |
| Nessler, J | 1 |
| Skrzypek, A | 1 |
| Wang, JZ | 2 |
| Du, RY | 2 |
| Ding, HX | 1 |
| Bai, BJ | 2 |
| Wang, G | 1 |
| Cui, GF | 1 |
| Zhong, ZH | 2 |
| Vora, A | 1 |
| Karnad, D | 1 |
| Goyal, V | 1 |
| Naik, A | 1 |
| Gupta, A | 1 |
| Lokhandwala, Y | 1 |
| Kulkarni, H | 1 |
| Singh, BN | 3 |
| Kirkutis, A | 1 |
| Poviliŭnas, A | 1 |
| Griciene, P | 1 |
| Polena, S | 1 |
| Yang, S | 1 |
| Yalamanchi, G | 1 |
| Gintautas, J | 1 |
| De Clercq, D | 1 |
| van Loon, G | 1 |
| Baert, K | 1 |
| Tavernier, R | 1 |
| Croubels, S | 1 |
| De Backer, P | 1 |
| Deprez, P | 1 |
| Oliveira, PF | 1 |
| Salgado, MC | 1 |
| Fazan, R | 1 |
| Aguiar, CA | 1 |
| Salgado, HC | 1 |
| Oral, H | 1 |
| Pappone, C | 1 |
| Chugh, A | 2 |
| Good, E | 1 |
| Bogun, F | 2 |
| Pelosi, F | 1 |
| Bates, ER | 1 |
| Lehmann, MH | 1 |
| Vicedomini, G | 1 |
| Augello, G | 1 |
| Agricola, E | 1 |
| Sala, S | 1 |
| Santinelli, V | 1 |
| Morady, F | 2 |
| Omeroglu, G | 1 |
| Kalugina, Y | 1 |
| Ersahin, C | 1 |
| Wojcik, EM | 1 |
| Kruchinova, OA | 1 |
| Zingilevskiĭ, K | 1 |
| Xin, LP | 1 |
| Wang, CG | 1 |
| Kobayashi, K | 1 |
| Horiguchi, T | 1 |
| Kondo, R | 1 |
| Shiga, M | 1 |
| Hirose, M | 1 |
| Itou, T | 1 |
| Torigoe, H | 1 |
| Hayashi, N | 1 |
| Ouhira, D | 1 |
| Jong, GP | 1 |
| Chang, MH | 1 |
| Chang, TC | 1 |
| Chou, P | 1 |
| Fu, CY | 1 |
| Tien, LY | 1 |
| Chen, CY | 1 |
| Ma, TC | 1 |
| Fradi, I | 1 |
| Mokaddem, A | 1 |
| Selmi, K | 1 |
| Boujnah, MR | 1 |
| Wang, K | 1 |
| Matsumoto, M | 1 |
| Abuladze, GV | 1 |
| Dzhindzholiia, NA | 1 |
| Dzhashi, IA | 1 |
| Narsiia, EV | 1 |
| Gudzhedzhiani, LA | 1 |
| Rizos, I | 1 |
| Tsiodras, S | 1 |
| Rigopoulos, AG | 1 |
| Dragomanovits, S | 1 |
| Kalogeropoulos, AS | 1 |
| Papathanasiou, S | 1 |
| Sakadakis, EA | 1 |
| Kremastinos, DT | 1 |
| Blank, W | 1 |
| Braun, B | 1 |
| Sanmartí, A | 1 |
| Permanyer-Miralda, G | 1 |
| Castellanos, JM | 1 |
| Foz-Sala, M | 1 |
| Galard, RM | 1 |
| Soler-Soler, J | 1 |
| Chiale, PA | 2 |
| Halpern, MS | 1 |
| Nau, GJ | 1 |
| Tambussi, AM | 1 |
| Przybylski, J | 1 |
| Lázzari, JO | 1 |
| Elizari, MV | 2 |
| Rosenbaum, MB | 1 |
| Vancrombreucq, JC | 1 |
| Sergysels, R | 1 |
| Steinbeck, G | 1 |
| Manz, M | 1 |
| Lüderitz, B | 1 |
| Reñe, JM | 1 |
| Buenestado, J | 1 |
| Pais, B | 1 |
| Piñol, MC | 1 |
| Zarembski, DG | 1 |
| Nolan, PE | 1 |
| Slack, MK | 1 |
| Caruso, AC | 1 |
| Chun, SH | 1 |
| Sager, PT | 1 |
| Stevenson, WG | 1 |
| Nademanee, K | 1 |
| Middlekauff, HR | 1 |
| Zehender, M | 2 |
| Just, H | 2 |
| Disch, DL | 2 |
| Greenberg, ML | 2 |
| Holzberger, PT | 1 |
| Malenka, DJ | 2 |
| Birkmeyer, JD | 1 |
| Skoularigis, J | 1 |
| Röthlisberger, C | 1 |
| Skudicky, D | 1 |
| Essop, MR | 1 |
| Wisenbaugh, T | 1 |
| Sareli, P | 1 |
| Alves, LE | 1 |
| Rose, EP | 1 |
| Kerin, NZ | 3 |
| Ansari-Leesar, M | 1 |
| Faitel, K | 3 |
| Narala, C | 1 |
| Frumin, H | 2 |
| Cohen, A | 1 |
| Naini, M | 1 |
| Williams, MJ | 1 |
| Low, CJ | 1 |
| Restieaux, NJ | 1 |
| Falcone, RA | 1 |
| Armstrong, WF | 1 |
| Ortiz, M | 1 |
| Gaete, L | 1 |
| Asenjo, R | 1 |
| Fernández, F | 1 |
| Saavedra, I | 1 |
| Storch, HD | 1 |
| Tonet, J | 2 |
| Hidden, F | 1 |
| Naditch, L | 1 |
| Coutte, R | 1 |
| Himbert, C | 1 |
| Frank, R | 2 |
| Toyama, J | 1 |
| Kamiya, K | 1 |
| Cheng, J | 1 |
| Lee, JK | 1 |
| Suzuki, R | 1 |
| Kodama, I | 1 |
| Opolski, G | 2 |
| Stanisławska, J | 1 |
| Górecki, A | 1 |
| Swiecicka, G | 1 |
| Torbicki, A | 2 |
| Kraska, T | 1 |
| Neri, R | 1 |
| Palermo, P | 1 |
| Cesario, AS | 1 |
| Baragli, D | 1 |
| Amici, E | 1 |
| Gambelli, G | 1 |
| Hancock, EW | 1 |
| Piepoli, M | 1 |
| Villani, GQ | 2 |
| Ponikowski, P | 1 |
| Wright, A | 1 |
| Flather, MD | 1 |
| Coats, AJ | 1 |
| Eichhorn, EJ | 1 |
| Hamdan, MH | 1 |
| Lau, CP | 1 |
| Ayers, GM | 1 |
| Kochiadakis, GE | 1 |
| Igoumenidis, NE | 1 |
| Parthenakis, FI | 1 |
| Chlouverakis, GI | 1 |
| López-Gómez, D | 1 |
| Nicolás, J | 1 |
| Frigola, JM | 1 |
| Manito, N | 1 |
| Esplugas, E | 1 |
| Yu, WC | 1 |
| Lin, YK | 1 |
| Tai, CT | 1 |
| Tsai, CF | 1 |
| Hsieh, MH | 1 |
| Chen, CC | 1 |
| Hsu, TL | 1 |
| Ding, YA | 1 |
| Chang, MS | 1 |
| Capucci, A | 1 |
| Aschieri, D | 1 |
| Rosi, A | 1 |
| Piepoli, MF | 1 |
| Khand, AU | 1 |
| Rankin, AC | 1 |
| Kaye, GC | 1 |
| Cleland, JG | 1 |
| Kosior, D | 1 |
| Stolarz, P | 1 |
| Dawidowska, R | 1 |
| Zawadzka, M | 1 |
| Szulc, M | 1 |
| Kołodziej, P | 1 |
| Stopiński, M | 1 |
| Janion, M | 1 |
| Achremczyk, P | 1 |
| Lewandowski, Z | 1 |
| Nielsen, KD | 1 |
| Møller, S | 1 |
| Grönefeld, GC | 1 |
| Li, YG | 1 |
| Louis, R | 1 |
| Melon, P | 1 |
| Kassab, A | 1 |
| Soyeur, D | 1 |
| Siniakowicz, RM | 1 |
| Narula, D | 1 |
| Suster, B | 1 |
| Steinberg, JS | 1 |
| Galperín, J | 1 |
| Molina, RT | 1 |
| Ledesma, R | 1 |
| Scapín, AO | 1 |
| Vázquez Blanco, M | 1 |
| Teo, KK | 1 |
| Mookadam, F | 1 |
| Trzpuc, TD | 1 |
| Shidham, VB | 1 |
| Rao, RN | 1 |
| Bilchick, KC | 1 |
| Fetics, B | 1 |
| Djoukeng, R | 1 |
| Fisher, SG | 1 |
| Fletcher, RD | 1 |
| Singh, SN | 1 |
| Nevo, E | 1 |
| Berger, RD | 1 |
| Metelitsa, VI | 1 |
| Matveeva, LS | 1 |
| Borisova, GA | 1 |
| Lupanov, VP | 1 |
| De'Thomatis, M | 1 |
| Falciola, N | 1 |
| Gallesio, R | 1 |
| Swan, JH | 1 |
| Chisholm, AW | 1 |
| Villain, E | 1 |
| Bonnet, D | 1 |
| Attali, T | 1 |
| Da Cruz, E | 1 |
| Marchal, C | 1 |
| Gournay, V | 1 |
| Kachaner, J | 1 |
| Lévy, S | 1 |
| Lauribe, P | 1 |
| Dolla, E | 1 |
| Kou, W | 1 |
| Kadish, A | 1 |
| Calkins, H | 1 |
| Pagannelli, F | 1 |
| Moyal, C | 1 |
| Bremondy, M | 1 |
| Schork, A | 1 |
| Hohnloser, S | 1 |
| Müller, B | 1 |
| Labate, FD | 1 |
| Borghi, M | 1 |
| Georges, JL | 1 |
| Normand, JP | 1 |
| Lenormand, ME | 1 |
| Schwob, J | 1 |
| Gosselink, AT | 1 |
| Crijns, HJ | 2 |
| Van Gelder, IC | 2 |
| Hillige, H | 1 |
| Wiesfeld, AC | 1 |
| Lie, KI | 2 |
| Winslow, E | 1 |
| Campbell, JK | 1 |
| Barron, E | 1 |
| Guarnieri, T | 1 |
| Tomaselli, G | 1 |
| Griffith, LS | 1 |
| Brinker, J | 1 |
| Van Gilst, WH | 1 |
| Hillege, H | 1 |
| Gosselink, AM | 1 |
| Motté, G | 1 |
| Slama, M | 1 |
| Drieu, L | 1 |
| Belokon', NA | 1 |
| Shkol'nikova, MA | 1 |
| Belozerov, IuM | 1 |
| Makarov, LM | 1 |
| Shvarkov, SB | 1 |
| Scanavacca, MI | 1 |
| Sosa, EA | 1 |
| Lee, JH | 1 |
| Bellotti, G | 1 |
| Pileggi, F | 1 |
| Teasdale, S | 1 |
| Downar, E | 1 |
| Fauchier, JP | 1 |
| Cosnay, P | 1 |
| Rouesnel, P | 1 |
| Moquet, B | 1 |
| Huguet, R | 1 |
| Wajman, A | 1 |
| Marinchak, RA | 1 |
| O'Connor, KM | 1 |
| Friehling, TD | 1 |
| Kowey, PR | 1 |
| Fontaine, G | 1 |
| Grosgogeat, Y | 1 |
| Chatterjee, K | 1 |
| Tuzcu, EM | 1 |
| Gilbo, J | 1 |
| Masterson, M | 1 |
| Maloney, JD | 1 |
| Vorob'ev, LP | 1 |
| Kaziulin, AN | 1 |
| Peters, KG | 1 |
| Kienzle, MG | 1 |
| Lipnitskiĭ, TN | 1 |
| Pilipchuk, VP | 1 |
| Kotsuta, GI | 1 |
| Gudim, EV | 1 |
| Perelman, MS | 1 |
| McKenna, WJ | 1 |
| Rowland, E | 1 |
| Krikler, DM | 1 |
| Huang, ZD | 1 |
| Deng, HF | 1 |
| Zhang, BX | 1 |
| Bauman, JL | 1 |
| Berk, SI | 1 |
| Hariman, RJ | 1 |
| Langenberg, PW | 1 |
| Deal, BJ | 1 |
| Beckman, K | 1 |
| Brownstein, S | 1 |
| Gallastegui, J | 1 |
| Guarino, H | 1 |
| Gensous, D | 1 |
| Coste, T | 1 |
| Merrouche, Y | 1 |
| Duchatelle, V | 1 |
| Huc, D | 1 |
| Rautureau, J | 1 |
| Babany, G | 1 |
| Mallat, A | 1 |
| Zafrani, ES | 1 |
| Saint-Marc Girardin, MF | 1 |
| Carcone, B | 1 |
| Dhumeaux, D | 1 |
| Gold, RL | 1 |
| Haffajee, CI | 1 |
| Charos, G | 1 |
| Sloan, K | 1 |
| Baker, S | 1 |
| Alpert, JS | 1 |
| Blevins, RD | 1 |
| Rubenfire, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ultrasound-assessed Internal Jugular Vein Distensibility to Predict Right Atrial Pressure and Other Hemodynamic Parameters in Patients With Advanced Chronic Heart Failure[NCT03874312] | 200 participants (Anticipated) | Observational | 2017-10-18 | Active, not recruiting | |||
| N-3 Polyunsaturated Fatty Acids (n-3 PUFAs) in the Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion. A Prospective Randomized Study.[NCT01198275] | Phase 3 | 199 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Acute Mechanical Response to Anti-arrhythmic Drug Therapy[NCT02575534] | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to No enrollment in study.) | |||
| A Randomized, Double Blind, Placebo Controlled, Parallel Group Trial for Assessing the Clinical Benefit of Dronedarone 400mg BID on Top of Standard Therapy in Patients With Permanent Atrial Fibrillation and Additional Risk Factors[NCT01151137] | Phase 3 | 3,236 participants (Actual) | Interventional | 2010-07-31 | Terminated (stopped due to The study was stopped because of safety concerns) | ||
| Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Change and Improve Outcomes in Persons With First-Detected Atrial Fibrillation[NCT05130268] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2021-10-29 | Active, not recruiting | ||
| Colchicine for the Prevention of Atrial Fibrillation Recurrence After Electrical Cardioversion of Persistent Atrial Fibrillation.[NCT02582190] | Phase 3 | 0 participants (Actual) | Interventional | 2017-12-02 | Withdrawn (stopped due to Investigational Medicinal Product Supplies) | ||
| Inhibition of Atrial Fibrillation by Elimination of Transitional Mechanisms[NCT02758002] | 0 participants (Actual) | Interventional | 2016-01-28 | Withdrawn | |||
| Tailored Treatment of Permanent Atrial Fibrillation - TTOP-AF[NCT00514735] | Phase 3 | 210 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI[NCT01182376] | Phase 3 | 33 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias[NCT03413150] | 80 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| Home-based Videoplethysmographic Detection of Atrial Fibrillation[NCT04267133] | 256 participants (Actual) | Interventional | 2018-05-24 | Completed | |||
| Congestive Heart Failure Atrial Arrhythmia Monitoring and Pacing (CHAMP)[NCT00156728] | Phase 4 | 172 participants | Interventional | 2003-10-31 | Completed | ||
| Efficacy and Safety of Dual Direct Current Cardioversion Versus Single Direct Current Cardioversion as an Initial Treatment Strategy in Obese Patients[NCT04539158] | 200 participants (Anticipated) | Interventional | 2020-08-07 | Recruiting | |||
| Double Sequence External Defibrillation: A Randomized Controlled Trial in Patients With Atrial Fibrillation Refractory to DC Cardioversion[NCT03827915] | 100 participants (Anticipated) | Interventional | 2019-01-21 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Sinus Rhythm maintenance means no Atrial Fibrillation recurrence at one-year follow up. Patients with successful electrical cardioversion (DCCV)underwent weekly clinical and electrocardiographic controls for the first three weeks following cardioversion. Subsequently, follow up visits with performance of clinical evaluation, ECG, and a 24-hour Holter monitoring were performed at 1, 3, 6 and 12 months after DCCV. (NCT01198275)
Timeframe: one year
| Intervention | partecipants (Number) |
|---|---|
| n-3 PUFAs | 61 |
| Placebo | 34 |
Deaths were classified according to the primary cause of death. (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Any death | - Cardiovascular death | --- Cardiac arrhythmic death | |
| Dronedarone | 25 | 21 | 13 |
| Placebo | 13 | 10 | 4 |
AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study. (NCT01151137)
Timeframe: from first study drug intake up to 10 days after the last study drug intake
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Any AE | - Any serious AE | - Any AE leading to death | - Any AE leading to treatment discontinuation | - Any AE leading to hospitalization | |
| Dronedarone | 797 | 113 | 4 | 212 | 95 |
| Placebo | 600 | 77 | 0 | 80 | 71 |
(NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| MI or unstable angina pectoris | - MI | Stroke | - Ischemic stroke | Systemic arterial embolism | Episode of heart failure | - Hospitalization due to heart failure | Unplanned hospitalization for cardiovascular cause | |
| Dronedarone | 15 | 3 | 23 | 18 | 1 | 115 | 43 | 113 |
| Placebo | 8 | 2 | 10 | 9 | 0 | 55 | 24 | 59 |
"First co-primary outcome was defined as the first event among stroke, systemic arterial embolism, Myocardial Infarctions [MI], or cardiovascular death.~Second co-primary outcome was defined as the first event among unscheduled cardiovascular hospitalization or death from any cause.~Both co-primary outcomes were determined based on the central review and adjudication by a blinded Adjudication Committee of all reported deaths (from any cause), MI, systemic arterial embolisms, strokes, Transient Ischemic Attacks [TIA], Heart Failure hospitalization and unplanned hospitalisations for cardiovascular cause." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | participants (Number) | |
|---|---|---|
| First co-primary endpoint | Second co-primary endpoint | |
| Dronedarone | 43 | 127 |
| Placebo | 19 | 67 |
"Time to cardiovascular death was defined as the time from randomization to the death.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | proportion of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cumulative incidence at 14 days | Cumulative incidence at 30 days | Cumulative incidence at 90 days | Cumulative incidence at 180 days | Cumulative incidence at 270 days | Cumulative incidence at 360 days | |
| Dronedarone | 0.003 | 0.005 | 0.008 | 0.022 | 0.026 | 0.026 |
| Placebo | 0.001 | 0.003 | 0.004 | 0.004 | 0.027 | 0.027 |
"Time to first co-primary outcome was defined as the time from randomization to the first event among stroke, systemic arterial embolism, MI or cardiovascular death.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | proportion of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cumulative incidence at 14 days | Cumulative incidence at 30 days | Cumulative incidence at 90 days | Cumulative incidence at 180 days | Cumulative incidence at 270 days | Cumulative incidence at 360 days | |
| Dronedarone | 0.009 | 0.013 | 0.021 | 0.042 | 0.045 | 0.045 |
| Placebo | 0.002 | 0.003 | 0.007 | 0.013 | 0.038 | 0.038 |
"Time to second co-primary outcome was defined as the time from randomization to the first event among unscheduled cardiovascular hospitalization or death from any cause.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | proportion of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cumulative incidence at 14 days | Cumulative incidence at 30 days | Cumulative incidence at 90 days | Cumulative incidence at 180 days | Cumulative incidence at 270 days | Cumulative incidence at 360 days | |
| Dronedarone | 0.020 | 0.034 | 0.069 | 0.110 | 0.137 | 0.137 |
| Placebo | 0.005 | 0.014 | 0.033 | 0.059 | 0.099 | 0.099 |
"A treatment success/failure up to the conclusion of the procedure for each subject in Ablation Management. A subject was considered successfully treated if the following were true:~Medtronic ablation catheters were used to achieve procedure success.~All accessible pulmonary veins were isolated.~At least 50% reduction of complex fractionated atrial electrograms mapped and ablated with Medtronic ablation catheters.~Sinus rhythm was achieved upon leaving the electrophysiology lab (±cardioversion)." (NCT00514735)
Timeframe: Procedure conclusion
| Intervention | percentage of participants (Mean) |
|---|---|
| Ablation Management | 92.8 |
The primary endpoint for acute safety was a success/failure variable calculated for each subject in Ablation Management at the 7 day post-procedure time point. Any subject with at least one adverse event adjudicated by the Data Safety Monitoring Board as both serious and either probably or definitely procedure and/or device-related occurring within 7 days of the ablation procedure was considered an acute safety failure, regardless of whether the event occurred following the index or retreatment ablation procedure. (NCT00514735)
Timeframe: 7 days
| Intervention | percentage of participants (Mean) |
|---|---|
| Ablation Management | 12.3 |
"The chronic efficacy endpoint was a treatment success/failure measure for each subject computed at 6 months. Treatment success included:~A 90% reduction in clinically significant atrial fibrillation from baseline to the 6 month time point based on a Holter recording. Clinically significant atrial fibrillation was defined as sustained atrial fibrillation lasting more than 10 minutes.~The subject was off all antiarrhythmic drugs at 6 months (Ablation Management arm only)~The Investigator judged all procedures to be acutely successful (Ablation Management arm only)." (NCT00514735)
Timeframe: 6 months
| Intervention | percentage of participants with success (Number) |
|---|---|
| Ablation Management | 56 |
| Medical Management | 26 |
The primary endpoint for chronic safety was a success/failure variable calculated for each subject at 6 months. Any subject that had at least one adverse event that met designated seriousness and relatedness criteria for the particular treatment group as adjudicated by the Data Safety Monitoring Board was considered a chronic safety failure. Adverse events in Ablation Management that were acute (≤7 days) were not included in the chronic safety primary endpoint. Given the disparity in the length of time at risk between treatment arms,the Chronic Safety endpoint was not statistically powered. (NCT00514735)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Ablation Management | 9 |
| Medical Management | 3 |
The SF-36 questionnaire was administered to subjects at baseline, 1, 3 and 6 month visits. The SF-36 is a multi-purpose, short-form health survey with only 36 questions. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based Physical Component Score and Mental Component Score. The possible range for Physical Component Score and Mental Component Score is 0 to 100. The higher score, the better quality of life. (NCT00514735)
Timeframe: 6 months
| Intervention | Scores on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Physical Component Score at Baseline | Physical Component Score at 1 Month | Physical Component Score at 3 Months | Physical Component Score at 6 Months | Mental Component Score at Baseline | Mental Component Score at 1 Month | Mental Component Score at 3 Months | Mental Component Score at 6 Months | |
| Ablation Management | 42.54 | 45.61 | 48.30 | 49.12 | 47.19 | 51.53 | 53.42 | 53.45 |
| Medical Management | 42.26 | 43.05 | 43.99 | 44.98 | 47.99 | 48.96 | 48.97 | 50.06 |
The severity of subject's atrial fibrillation related symptoms on a scale from 1 (no symptoms) to 5 (most severe). The symptoms included palpitations, fatigue, shortness of breath, lightheadedness or dizziness, and lack of energy during exertion or exercise. The scores were tabulated at the 1, 3 and 6 month follow-up visits. Scores could range from 5 to 25, indicating a spectrum of subject status from asymptomatic to severely symptomatic. (NCT00514735)
Timeframe: 6 months
| Intervention | AF Symptom Severity Score (Mean) | |||
|---|---|---|---|---|
| Measurement at Baseline | Measurement at 1 Month | Measurement at 3 Months | Measurement at 6 Months | |
| Ablation Management | 12.38 | 8.95 | 7.56 | 7.58 |
| Medical Management | 12.72 | 9.90 | 10.03 | 9.84 |
Left atrial diameter (LAD), as measured by transthoracic echocardiogram (TTE) looking at the longitudinal long axis at baseline and at the 6 month follow-up visit in both the Ablation and Medical Management arms. (NCT00514735)
Timeframe: 6 months
| Intervention | centimeters (Mean) | |
|---|---|---|
| Measurement at Baseline | Measurement at 6 Months | |
| Ablation Management | 4.5 | 4.4 |
| Medical Management | 4.6 | 4.6 |
Left ventricular ejection fraction (LVEF), as measured by transthoracic echocardiogram at baseline and 6 months in both the Ablation and Medical Management arms. (NCT00514735)
Timeframe: 6 months
| Intervention | percent (Mean) | |
|---|---|---|
| Measurement at Baseline | Measurement at 6 Months | |
| Ablation Management | 54.7 | 58.3 |
| Medical Management | 54.9 | 57.0 |
The change in left atrial fibrosis percentage, as measured on a scale, using MRI imaging, from baseline to the end of treatment. (NCT01182376)
Timeframe: baseline, 1 year
| Intervention | percentage of fibrosis (Mean) |
|---|---|
| Placebo | 24.6 |
| Multaq® (Dronedarone) | 16.8 |
The outcome measure is the AUC of the curve obtained from the ROC analysis. The curve is a combination of specificity and sensitivity of detecting atrial fibrillation. The range of the curve is 0.5-1.0 where 0.5 would be random detection of atrial fibrillation and 1.0 would be perfect performance. (NCT04267133)
Timeframe: 2 weeks
| Intervention | probability (Number) |
|---|---|
| All Participants | 0.74 |
22 reviews available for amiodarone and Chronic Illness
| Article | Year |
|---|---|
Use of statins, amiodarone, direct oral anticoagulants and NSAIDs in chronic liver disease: a guide for general clinicians.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; A | 2020 |
Dysthyroidism and Chronic Heart Failure: Pathophysiological Mechanisms and Therapeutic Approaches.
Topics: Amiodarone; Chronic Disease; Heart Failure; Humans; Hyperthyroidism; Hypothyroidism | 2018 |
[Non-autoimmune thyroiditis].
Topics: Amiodarone; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Diagnosis, Differential; Gluco | 2014 |
[Treatment of atrial fibrillation in every days practice].
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Chronic D | 2008 |
[Heart failure].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2002 |
[Pharmacological treatment of heart failure].
Topics: Acute Disease; Adrenergic beta-Antagonists; Amiodarone; Angiotensin Receptor Antagonists; Angiotensi | 2003 |
[Guidelines for the evaluation and management of chronic heart failure].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2003 |
[The modern view on the role of inflammatory factors in chronic heart failure and possibilities of pharmacological modification].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory | 2003 |
Catheter ablation as first-line therapy for patients with symptomatic atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Catheter Ablati | 2007 |
[Cirrhosis caused by amiodarone].
Topics: Aged; Amiodarone; Biopsy; Chronic Disease; Female; Humans; Liver; Liver Cirrhosis | 1995 |
Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; | 1995 |
Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone.
Topics: Aged; Amiodarone; Atrial Fibrillation; Chronic Disease; Decision Support Techniques; Humans; Markov | 1994 |
Therapeutic strategies for atrial fibrillation. The value of decision analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; D | 1996 |
Ion channel blockers in the treatment of chronic heart failure.
Topics: Amiodarone; Animals; Calcium Channel Blockers; Chronic Disease; Heart Failure; Humans; Potassium Cha | 1996 |
Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Chronic Disease; Cont | 1997 |
Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure.
Topics: Amiodarone; Anti-Arrhythmia Agents; Chronic Disease; Heart Failure; Humans; Odds Ratio; Randomized C | 1998 |
Beta-blockade and amiodarone therapy: twin brothers from different parents.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Carvedilol; Chronic Dis | 1998 |
[The use of oral amiodarone as a chronic treatment in a patient with prior fulminant hepatitis due to intravenous amiodarone].
Topics: Acute Disease; Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Chemical and Drug Induced L | 1999 |
Systematic review of the management of atrial fibrillation in patients with heart failure.
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Chronic Dise | 2000 |
Primary prevention in chronic ischemic heart disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Chronic Disease; Death, Sudden, Cardiac; Defibrillators, Implant | 2002 |
[Medical therapy of chronic coronary insufficiency].
Topics: Amiodarone; Angina Pectoris; Chronic Disease; Coronary Disease; Digitalis Glycosides; Humans; Lidofl | 1978 |
[Drug treatment of patients with the chronic form of atrial fibrillation in counterindications for cardioversion (a review)].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anabolic Agents; Atrial Fibrillation; Calcium Channel Block | 1985 |
27 trials available for amiodarone and Chronic Illness
| Article | Year |
|---|---|
Effectiveness of VF induction with DC fibber versus conventional induction methods in patients on chronic amiodarone therapy.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Chronic Disease; Defibrillators, | 2013 |
Prognostic value of the physical examination in patients with heart failure and atrial fibrillation: insights from the AF-CHF trial (atrial fibrillation and chronic heart failure).
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Convert | 2014 |
[Therapeutic effects of amiodarone and metoprolol on chronic heart failure complicated by ventricular arrhythmia].
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Chronic Disease; Drug Therap | 2009 |
Tc-99m sestamibi thyroid imaging in patients on chronic amiodarone treatment: a comparison with Tc-99m pertechnetate imaging.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Chronic Disease; Female; Humans; | 2010 |
Comparison of surgical cut and sew versus radiofrequency pulmonary veins isolation for chronic permanent atrial fibrillation: a randomized study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Chronic Disease; F | 2010 |
n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electric Countershoc | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.
Topics: Adult; Aged; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Calcium Cha | 2003 |
Control of heart rate versus rhythm in rheumatic atrial fibrillation: a randomized study.
Topics: Adult; Amiodarone; Atrial Fibrillation; Chronic Disease; Double-Blind Method; Female; Heart Rate; Hu | 2004 |
Cardiac rate normalization in chronic atrial fibrillation: comparison of long-term efficacy of treatment with amiodarone versus AV node ablation and permanent His-bundle pacing.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle of His; Car | 2004 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
Circumferential pulmonary-vein ablation for chronic atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Ch | 2006 |
[The clinical study of circumferential ablation around orifice of pulmonary vein by radiofrequency energy with chronic atrial fibrillation undergoing rheumatic valvular heart surgery].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Chronic Dis | 2006 |
Long-term efficacy and safety of very-low-dose amiodarone treatment for the maintenance of sinus rhythm in patients with chronic atrial fibrillation after successful direct-current cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Chronic Disease; C | 2006 |
[Amiodarone and verapamil/quinidine in treatment of patients with chronic atrial fibrillation].
Topics: Aged; Amiodarone; Atrial Fibrillation; Chronic Disease; Dose-Response Relationship, Drug; Drug Admin | 1994 |
The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillati | 1996 |
Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electrocardiography; | 1999 |
Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electric Coun | 2000 |
[Should sinus rhythm be restored in patients with chronic atrial fibrillation? Preliminary results from the Polish "Hot Cafe" study].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Chronic Disease; Dicu | 1999 |
Amiodarone for rapid cardioversion of chronic atrial tachyarrhythmia?
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; | 2000 |
Efficacy and safety of transvenous atrial cardioversion in patients with mitral valve disease and long-standing atrial fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Catheterizati | 2000 |
Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Chronic Disease; Double-Blind Method; Electric Counter | 2001 |
[Cordaron and nonachlasine in treatment of chronic coronary insufficiency].
Topics: Adrenergic beta-Agonists; Amiodarone; Benzofurans; Chronic Disease; Clinical Trials as Topic; Corona | 1975 |
A randomized comparison of external and internal cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Body Weight; Cardiac Catheterization; Chronic Disease; Electric Cou | 1992 |
A randomized comparison of external and internal cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Body Weight; Cardiac Catheterization; Chronic Disease; Electric Cou | 1992 |
A randomized comparison of external and internal cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Body Weight; Cardiac Catheterization; Chronic Disease; Electric Cou | 1992 |
A randomized comparison of external and internal cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Atrial Fibrillation; Body Weight; Cardiac Catheterization; Chronic Disease; Electric Cou | 1992 |
Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up.
Topics: Amiodarone; Atrial Fibrillation; Chronic Disease; Drug Therapy, Combination; Electrocardiography; Fe | 1992 |
Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter.
Topics: Amiodarone; Atrial Fibrillation; Chronic Disease; Clinical Protocols; Electric Countershock; Follow- | 1992 |
[Comparative study of the efficacy of propafenone and amiodarone in the treatment of chronic ventricular extrasystole].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Cardiac Complexes, Pre | 1986 |
78 other studies available for amiodarone and Chronic Illness
| Article | Year |
|---|---|
Learning from errors: unnecessary intensive care unit admissions.
Topics: Administration, Intravenous; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Chronic Disease; | 2017 |
Cardiac autonomic modulation and long-term use of amiodarone in patients with chronic Chagasic cardiopathy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Autonomic Nervous System; Chagas Car | 2018 |
Developing a list of high-alert medications for patients with chronic diseases.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Amiodarone; Analgesics, Opioid; Anti-Arrhythmi | 2014 |
Improvement of the myocardial performance index in atrial fibrilation patients treated with amiodarone after cardioversion.
Topics: Aged; Amiodarone; Analysis of Variance; Atrial Fibrillation; Chronic Disease; Cohort Studies; Combin | 2015 |
Impacts of Surgically Performed Renal Denervation on the Cardiovascular and Electrophysiological Variables in the Chronic Atrioventricular Block Dogs - Comparison With Those of Amiodarone Treatment.
Topics: Amiodarone; Animals; Atrioventricular Block; Blood Pressure; Chronic Disease; Denervation; Dogs; Kid | 2016 |
Risk factors of vitamin K antagonist overcoagulation. A case-control study in unselected patients referred to an emergency department.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Amiodarone; Anticoagulants; Blood Coagulation Disorde | 2008 |
Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Cardiotonic Agents; Chronic Disease; Dobut | 2009 |
Implantable cardioverter defibrillator therapy for patients with chronic Chagas' disease: a randomized trial may not be necessary in high-risk patients.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Chagas Cardiomyopathy; Chagas Disease; Chronic Disease; | 2009 |
Amiodarone and itraconazole: a rational therapeutic approach for the treatment of chronic Chagas' disease.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Chagas Disease; Chronic Disease; Drug Therapy, Combinat | 2009 |
[Comparison of the results of irrigated monopolar and bipolar radiofrequency ablation in the surgical treatment of atrial fibrillation].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ab | 2011 |
Noninvasive time and frequency predictors of long-standing atrial fibrillation early recurrence after electrical cardioversion.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; E | 2011 |
Incidence and prevalence of hypothyroidism in patients affected by chronic heart failure: role of amiodarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Chronic Disease; Cohort Studies; Female; Follow-Up Studies | 2012 |
Prediction of long-term outcomes of catheter ablation of persistent atrial fibrillation by parameters of preablation DC cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Catheter Ablation; C | 2012 |
Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Dogs; Dose-Respo | 2002 |
Re: The patient with chronic epididymitis: characterization of an enigmatic syndrome.
Topics: Amiodarone; Anti-Arrhythmia Agents; Chronic Disease; Dose-Response Relationship, Drug; Epididymitis; | 2002 |
[Comparative effects of amiodarone, diltiazem, and atenolol on results of electrical cardioversion in patients with chronic atrial fibrillation].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Chronic Disease; Dil | 2002 |
Combined amiodarone and silymarin treatment, but not amiodarone alone, prevents sustained atrial flutter in dogs.
Topics: Amiodarone; Animals; Atrial Flutter; Chronic Disease; Dogs; Drug Therapy, Combination; Electrocardio | 2003 |
Impact of left atrial size reduction on chronic atrial fibrillation in mitral valve surgery.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pac | 2003 |
[Effect of cordaron on systolic and diastolic functions of the left ventricle in patients with a mixed form of chronic low cardiac output and cardiac arrhythmias].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Ou | 2003 |
Limited posterior left atrial linear radiofrequency ablation for patients with chronic atrial fibrillation undergoing rheumatic valvular heart surgery.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Catheter Ablation; Chronic Disease; Female; Heart Atri | 2004 |
Intravenous amiodarone treatment in horses with chronic atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Horse Diseases; H | 2006 |
Acute effect of amiodarone on cardiovascular reflexes of normotensive and renal hypertensive rats.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Baroreflex; Blood Pressure; Chemoreceptor Cells; Chroni | 2005 |
Amiodarone lung toxicity in a cardiac transplant candidate initially diagnosed by fine-needle aspiration: cytologic, histologic, and electronmicroscopic findings.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Biopsy, Fine-Needle; Chronic Disease; Cryptogenic Organizi | 2006 |
[Advantages of restoration and maintenance of sinus rhythm in middle aged patients with atrial fibrillation and chronic heart failure].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Female; Heart Failure; Hum | 2006 |
[A case of drug-induced pneumonitis due to amiodarone].
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Humans; | 2006 |
[Chronic atrial fibrillation in adults: direct current cardioversion or medical cardioversion].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electric Coun | 2006 |
In vivo electropharmacological effects of amiodarone and candesartan on atria of chronic atrioventricular block dogs.
Topics: Amiodarone; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Arrhythmia Agents; Benzimidazoles | 2007 |
[Dynamics of echocardiographic changes and the tactic of optimal therapy in patients with atrial fibrillation with chronical heart failure].
Topics: Adult; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fibrilla | 2007 |
Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; C-Reactive Protein | 2007 |
[Sonography of the thyroid--part 2: thyroid inflammation, impairmant of thyroid function and interventions].
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Chronic Disease; Female; Humans; Hyperthyroidism; | 2008 |
Chronic administration of amiodarone and thyroid function: a follow-up study.
Topics: Adult; Aged; Amiodarone; Benzofurans; Chronic Disease; Coronary Disease; Female; Follow-Up Studies; | 1984 |
Efficacy of amiodarone during long-term treatment of malignant ventricular arrhythmias in patients with chronic chagasic myocarditis.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Chagas Cardiomyopathy; Chronic Disease; | 1984 |
[Use of injectable amiodarone in patients with chronic respiratory insufficiency].
Topics: Aged; Amiodarone; Benzofurans; Blood Gas Analysis; Chronic Disease; Electrocardiography; Female; Hea | 1980 |
[Amiodarone in ventricular tachycardias].
Topics: Adult; Aged; Amiodarone; Benzofurans; Chronic Disease; Female; Heart Ventricles; Humans; Male; Middl | 1982 |
Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Evaluation Studies as Topic; | 1995 |
Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery.
Topics: Adult; Amiodarone; Atrial Fibrillation; Chronic Disease; Combined Modality Therapy; Electric Counter | 1993 |
Amiodarone in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Chronic Disease; Female; Humans | 1993 |
The effectiveness and safety of the simultaneous administration of quinidine and amiodarone in the conversion of chronic atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Chronic Disease; Drug Combinations; Electr | 1993 |
Tachycardia and cardiomyopathy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomegaly; Child; Chronic Disease; Electrocardiography; Femal | 1996 |
Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function, Left; Blood Flow Vel | 1996 |
[Plasma concentrations and amiodarone/desethylamiodarone relations in patients subjected to chronic treatment].
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Chromatography, High Pressure Liquid; Chronic Disease | 1996 |
Intravenous amiodarone for the conversion of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Humans; Injections, Intrav | 1996 |
[Combination of celiprolol and amiodarone in the treatment of recurrent ventricular tachycardia].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Celiprolol; Chronic Di | 1996 |
Drugs for chronic heart failure.
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia A | 1996 |
Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Chronic Disease; Comb | 1997 |
Internal cardioversion of chronic atrial fibrillation in patients.
Topics: Acenocoumarol; Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Chroni | 1997 |
A pulse of 27 in a man with chronic heart disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Drug Overdose; Drug Thera | 1997 |
Long-term outcome in patients with chronic atrial fibrillation after successful internal cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electric Countershoc | 1999 |
Early recurrence of atrial fibrillation after external cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Electric Countershoc | 1999 |
[How I treat...persistent atrial fibrillation, by internal cardioversion, in a patient with exreme obesity].
Topics: Alcoholism; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Body Mass Index | 2001 |
Diagnosis of amiodarone pulmonary toxicity with high-resolution computerized tomographic scan.
Topics: Acute Disease; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Amiodarone; Case-Control Studies; C | 2001 |
Pathologic quiz case: pulmonary infiltrates with characteristic light and electron microscopic features.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Chronic Disease; Collagen Diseases; Diagnosis, Differentia | 2002 |
Prognostic value of heart rate variability in chronic congestive heart failure (Veterans Affairs' Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Comorbidity; Death, | 2002 |
Control of recurrent supraventricular tachycardia with amiodarone hydrochloride.
Topics: Amiodarone; Anti-Arrhythmia Agents; Benzofurans; Cardiomyopathy, Hypertrophic; Chronic Disease; Elec | 1976 |
[Rhythmogenic cardiomyopathies of atrial origin in children. Myth or reality?].
Topics: Adrenergic beta-Antagonists; Amiodarone; Cardiomyopathies; Child; Chronic Disease; Electrocardiograp | 1992 |
[The use of high-dose amiodarone for cardioversion in patients with chronic atrial fibrillation].
Topics: Aged; Amiodarone; Atrial Fibrillation; Chronic Disease; Drug Evaluation; Heart Rate; Humans | 1992 |
Life-threatening thyrotoxicosis induced by amiodarone in patients with benign heart disease.
Topics: Aged; Amiodarone; Atrial Fibrillation; Chronic Disease; Female; Humans; Male; Middle Aged; Thyrotoxi | 1992 |
Effects of amiodarone on cardiac electrophysiology and inducibility of arrhythmias in chronically infarcted dogs: late arrhythmias, haemodynamics, and sympatholytic actions.
Topics: Action Potentials; Amiodarone; Animals; Arrhythmias, Cardiac; Chronic Disease; Dogs; Electrocardiogr | 1990 |
The interaction of antiarrhythmic drugs and the energy for cardioversion of chronic atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cerebrovascular Disorders; Chr | 1991 |
Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter.
Topics: Actuarial Analysis; Aged; Amiodarone; Analysis of Variance; Atrial Fibrillation; Atrial Flutter; Chr | 1991 |
[Treatment of arrhythmias in chronic cardiac insufficiency].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disea | 1990 |
[Chronic nonparoxysmal supraventricular tachycardia in children and adolescents].
Topics: Adolescent; Age Factors; Amiodarone; Anti-Arrhythmia Agents; Child; Child, Preschool; Chronic Diseas | 1990 |
[Empiric therapy with amiodarone in patients with chronic Chagas cardiomyopathy and sustained ventricular tachycardia].
Topics: Adult; Aged; Amiodarone; Chagas Cardiomyopathy; Chronic Disease; Female; Heart Rate; Humans; Male; M | 1990 |
Amiodarone and anaesthesia.
Topics: Administration, Oral; Amiodarone; Anesthesia, General; Arrhythmias, Cardiac; Cardiac Surgical Proced | 1990 |
Acute electrophysiologic effects and antiarrhythmic/antifibrillatory activity of intravenous amiodarone in a chronic feline infarction model.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cats; Chronic Disease; Electric Stimulation; Electrophy | 1989 |
[Efficacy of the combination of low doses of beta-blockers and amiodarone in the treatment of refractory ventricular tachycardia].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Chronic Disease; Drug Evaluation; | 1989 |
Amiodarone in chronic heart failure.
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Chronic Disease; Heart F | 1989 |
The usefulness of amiodarone in management of refractory supraventricular tachyarrhythmias.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Chronic Disease; Female; Humans; Ma | 1989 |
Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: complete recovery after restoration of sinus rhythm.
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Dilated; Chronic Disease; Electrocardiography; Hear | 1988 |
[Use of kordaron and Kinilentin in the permanent form of atrial fibrillation].
Topics: Adult; Amiodarone; Atrial Fibrillation; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; | 1987 |
A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Bepridil; Chron | 1987 |
[Postoperative therapeutic effect of amiodarone on the conversion of chronic atrial fibrillation in rheumatic heart disease].
Topics: Adult; Amiodarone; Atrial Fibrillation; Chronic Disease; Female; Heart Valve Diseases; Heart Valve P | 1987 |
Amiodarone for sustained ventricular tachycardia: efficacy, safety, and factors influencing long-term outcome.
Topics: Adolescent; Adult; Aged; Amiodarone; Chronic Disease; Female; Follow-Up Studies; Heart Function Test | 1987 |
[Efficacy of amiodarone in chronic stable coronary insufficiency].
Topics: Adult; Aged; Amiodarone; Angina Pectoris; Chronic Disease; Coronary Disease; Exercise Test; Female; | 1986 |
[Chronic hepatitis associated with the intake of amiodarone].
Topics: Aged; Aged, 80 and over; Amiodarone; Chemical and Drug Induced Liver Injury; Chronic Disease; Female | 1986 |
Chronic liver disease after low daily doses of amiodarone. Report of three cases.
Topics: Aged; Aged, 80 and over; Amiodarone; Angina Pectoris; Chemical and Drug Induced Liver Injury; Chroni | 1986 |
Amiodarone for refractory atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Chronic Disease; Drug Evaluation; Female; | 1986 |
Intravenous and oral loading versus oral loading alone with amiodarone for chronic refractory ventricular arrhythmias.
Topics: Administration, Oral; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Chronic Disease; Heart Ve | 1985 |